ABSTRACT

Posterior capsule opacification (PCO) is one of the most frequent complications in cataract surgery and likely to cause the second loss of vision. Proliferation and migration of postoperative remnants of lens epithelial cells (LECs) on the implanted intraocular lens (IOL) are the leading causes of PCO. Antiproliferative drugs can be an effective solution but also possess some problems including sudden release and accompanying adverse effects to surrounding normal tissues, which greatly limit the clinical trials. In this study, an antiproliferative drug Paclitaxel (Pac) -sustained released hyaluronic acid (HA) and chitosan (CHI) multilayer modified IOL with postoperatively long-term PCO prevention was fabricated via layer by layer (LbL) technique. Quartz crystal microbalance with dissipation monitoring (QCM-D) result shows that HA-Pac/CHI multilayer is modified onto IOL material via LbL technique successfully. The HA-Pac/CHI multilayer coating greatly improves the hydrophilicity of the IOL material surfaces without change the transmittance significantly, whereas the proliferation of LECs is distinctly reduced on the HA-Pac/CHI multilayer-modified surfaces. The drug release in vitro reveals that the multilayer modified IOL material is stable under physiological condition and has good sustained drug release property. All these results demonstrate that HA-Pac/CHI multilayer modified IOL material can effectively inhibit LECs proliferation which provides a novel approach for reducing of PCO incidence in clinical.

摘要

后囊混浊（PCO）是白内障手术中最常见的并发症之一，可能导致第二次视力丧失。人工晶状体（IOL）上晶状体上皮细胞（LEC）术后残留的增殖和迁移是PCO的主要原因。抗增殖药可能是一种有效的解决方案，但也存在一些问题，包括突然释放以及对周围正常组织的不良影响，这极大地限制了临床试验。在这项研究中，通过层层（LbL）技术制备了抗增殖药紫杉醇（Pac）-缓释透明质酸（HA）和壳聚糖（CHI）多层修饰的IOL，具有术后长期PCO预防作用。带有耗散监测的石英晶体微天平（QCM-D）结果表明，通过LbL技术成功将HA-Pac / CHI多层膜改性为IOL材料。HA-Pac / CHI多层涂层极大地改善了IOL材料表面的亲水性，而没有明显改变透射率，而在HA-Pac / CHI多层改性表面上，LEC的扩散明显减少。体外药物释放表明该多层改性的IOL材料在生理条件下是稳定的，并具有良好的持续药物释放性能。所有这些结果表明，HA-Pac / CHI多层改性IOL材料可有效抑制LECs的增殖，为临床降低PCO发生率提供了一种新方法。HA-Pac / CHI多层涂层极大地改善了IOL材料表面的亲水性，而没有明显改变透射率，而在HA-Pac / CHI多层改性表面上，LEC的扩散明显减少。体外药物释放表明该多层改性的IOL材料在生理条件下是稳定的，并具有良好的持续药物释放性能。所有这些结果表明，HA-Pac / CHI多层改性IOL材料可有效抑制LECs的增殖，为临床降低PCO发生率提供了一种新方法。HA-Pac / CHI多层涂层极大地改善了IOL材料表面的亲水性，而没有明显改变透射率，而在HA-Pac / CHI多层改性表面上，LEC的扩散明显减少。体外药物释放表明该多层改性的IOL材料在生理条件下是稳定的，并具有良好的持续药物释放性能。所有这些结果表明，HA-Pac / CHI多层改性IOL材料可有效抑制LECs的增殖，为临床降低PCO发生率提供了一种新方法。体外药物释放表明该多层改性的IOL材料在生理条件下是稳定的，并具有良好的持续药物释放性能。所有这些结果表明，HA-Pac / CHI多层改性IOL材料可有效抑制LECs的增殖，为临床降低PCO发生率提供了一种新方法。体外药物释放表明该多层改性的IOL材料在生理条件下是稳定的，并具有良好的持续药物释放性能。所有这些结果表明，HA-Pac / CHI多层改性IOL材料可有效抑制LECs的增殖，为临床降低PCO发生率提供了一种新方法。